Pathophysiology of the clinical manifestations of preeclampsia

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 3, 2007, Pages 543-549

  Hladunewich, Michelle ^a   Karumanchi, S Ananth ^b   Lafayette, Richard A ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR;

BLOOD; BLOOD CLOTTING DISORDER; ECLAMPSIA; FEMALE; HELLP SYNDROME; HUMAN; HYPERTENSION; KIDNEY DISEASE; PATHOPHYSIOLOGY; PLACENTA INSUFFICIENCY; PREECLAMPSIA; PREGNANCY; PROTEINURIA; REPRODUCTION; REVIEW;

ANGIOGENESIS INDUCING AGENTS; BLOOD COAGULATION DISORDERS; ECLAMPSIA; FEMALE; HELLP SYNDROME; HUMANS; HYPERTENSION; KIDNEY DISEASES; PLACENTAL INSUFFICIENCY; PLACENTATION; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA;

EID: 34250902669     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03761106     Document Type: Review

References (71)

1. Roberts JM: Preeclampsia: What we know and what we do not know. Semin Perinatol 24: 24-28, 2000
2. Lim KH, Zhou Y, Janatpour M, McMaster M, Bass K, Chun SH, Fisher SJ: Human cytotrophoblast differentiation/invasion is abnormal in pre-eclampsia. Am J Pathol 151: 1809-1818, 1997
3. Hershkovitz R, de Swiet M, Kingdom J: Mid-trimester placentation assessment in high-risk pregnancies using maternal serum screening and uterine artery Doppler. Hypertens Pregnancy 24: 273-280, 2005
4. Gomez O, Figueras F, Martinez JM, Del Rio M, Palacio M, Eixarch E, Puerto B, Coll O, Cararach V, Vanrell JA: Sequential changes in uterine artery blood flow pattern between the first and second trimesters of gestation in relation to pregnancy outcome. Ultrasound Obstet Gynecol 28: 802-808, 2006
5. Li H, Gudnason H, Olofsson P, Dubiel M, Gudmundsson S: Increased uterine artery vascular impedance is related to adverse outcome of pregnancy but is present in only one-third of late third-trimester pre-eclamptic women. Ultrasound Obstet Gynecol 25: 459-463, 2005
6. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP: L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 43: 832-836, 2004
7. Zhou Y, Damsky CH, Fisher SJ: Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest 99: 2152-2164, 1997
8. Zhou Y, Fisher SJ, Janatpour M, Genbacev O, Dejana E, Wheelock M, Damsky CH: Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 99: 2139-2151, 1997
9. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I: Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 291: R1085-R1093, 2006
10. Cowden Dahl KD, Fryer BH, Mack FA, Compernolle V, Maltepe E, Adelman DM, Carmeliet P, Simon MC: Hypoxia-inducible factors 1alpha and 2alpha regulate trophoblast differentiation. Mol Cell Biol 25: 10479-10491, 2005
11. Fisher SJ: The placental problem: Linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2: 53, 2004
12. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, Nose A, lba O, Tateishi E, Ogata N, Jyo N, Higashiyama S, Iwasaka T: Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 88: 22-29, 2001
13. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP: Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93: 1249-1257, 2003
14. Conrad KP, Vernier KA: Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats. Am J Physiol 257: R847-R853, 1989
15. Conrad KP, Joffe GM, Kruszyna H, Kruszyna R, Rochelle LG, Smith RP, Chavez JE, Mosher MD: Identification of increased nitric oxide biosynthesis during pregnancy in rats. FASEB J 7: 566-571, 1993
16. Danielson LA, Conrad KP: Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats. J Clin Invest 96: 482-490, 1995
17. Helmbrecht GD, Farhat MY, Lochbaum L, Brown HE, Yadgarova KT, Eglinton GS, Ramwell PW: L-arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am J Obstet Gynecol 175: 800-805, 1996
18. Holden DP, Fickling SA, Whitley GS, Nussey SS: Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 178: 551-556, 1998
19. Pettersson A, Hedner T, Milsom I: Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 77: 808-813, 1998
20. Teerlink T: HPLC analysis of ADMA and other methylated 1-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci August 21, 2006 [epub ahead of print]
21. Hladunewich MA, Derby GC, Lafayette RA, Blouch KL, Druzin ML, Myers BD: Effect of L-arginine therapy on the glomerular injury of preeclampsia: A randomized controlled trial. Obstet Gynecol 107: 886-895, 2006
22. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henriksen T: Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. Acta Obstet Gynecol Scand 83: 103-107, 2004
23. Hibbard JU, Shroff SG, Lang RM: Cardiovascular changes in preeclampsia. Semin Nephrol 24: 580-587, 2004
24. Bosio PM, McKenna PJ, Conroy R, O'Herlihy C: Maternal central hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol 94: 978-984, 1999
25. Carr DB, McDonald GB, Brateng D, Desai M, Thach CT, Easterling TR: The relationship between hemodynamics and inflammatory activation in women at risk for preeclampsia. Obstet Gynecol 98: 1109-1116, 2001
26. Easterling TR, Carr DB, Brateng D, Diederichs C, Schmucker B: Treatment of hypertension in pregnancy: Effect of atenolol on maternal disease, preterm delivery, and fetal growth. Obstet Gynecol 98: 427-433, 2001
27. Easterling TR, Brateng D, Schmucker B, Brown Z, Millard SP: Prevention of preeclampsia: A randomized trial of atenolol in hyperdynamic patients before onset of hypertension. Obstet Gynecol 93: 725-733, 1999
28. Novak J, Reckelhoff J, Bumgarner L, Cockrell K, Kassab S, Granger JP: Reduced sensitivity of the renal circulation to angiotensin II in pregnant rats. Hypertension 30: 580-584, 1997
29. Merrill DC, Karoly M, Chen K, Ferrario CM, Brosnihan KB: Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 18: 239-245, 2002
30. Valdes G, Germain AM, Corthorn J, Berrios C, Foradori AC, Ferrario CM, Brosnihan KB: Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 16: 117-122, 2001
31. Brown MA, Wang J, Whitworth JA: The renin-angiotensin-aldosterone system in pre-eclampsia. Clin Exp Hypertens 19: 713-726, 1997
32. Brown CE, Gant NF, Cox K, Spitz B, Rosenfeld CR, Maghess RR: Low-dose aspirin. II. Relationship of angiotensin II pressor responses, circulating eicosanoids, and pregnancy outcome. Am J Obstet Gynecol 163: 1853-1861, 1990
33. Sanchez-Ramos L, Briones DK, Kaunitz AM, Delvalle GO, Gaudier FL, Walker CD: Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin U-sensitive patients. Obstet Gynecol 84: 349-353, 1994
34. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103: 945-952, 1999
35. Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC: Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol 81: 79-83, 2003
36. AbdAlla S, Lother H, el Massiery A, Quitterer U: Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7: 1003-1009, 2001
37. Xia Y, Wen H, Bobst S, Day MC, Kellems RE: Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J Soc Gynecol Invest 10: 82-93, 2003
38. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558-569, 2005
39. de Alvarez RR: Renal glomerular tubular mechanisms during normal pregnancy. I. Glomerular filtration rate, Renal plasma flow and creatinine clearance. Am J Obstet Gynecol 75: 931-944, 1958
40. Chapman AB, Abraham WT, Zamudio S, Coffin C, Merouani A, Young D, Johnson A, Osorio F, Goldberg C, Moore LG, Dahms T, Schrier RW: Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int 54: 2056-2063, 1998
41. Lafayette RA, Druzin M, Sibley R, Derby G, Malik T, Huie P, Polhemus C, Deen WM, Myers BD: Nature of glomerular dysfunction in pre-eclampsia. Kidney Int 54: 1240-1249, 1998
42. Strevens H, Wide-Swensson D, Grubb A, Hansen A, Horn T, Ingemarsson I, Larsen S, Nyengaard JR, Torffvit O, Willner J, Olsen S: Serum cystatin C reflects glomerular endotheliosis in normal, hypertensive and pre-eclamptic pregnancies. BJOG 110: 825-830, 2003
43. Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, Willner J, Olsen S: Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 110: 831-836, 2003
44. Fisher KA, Luger A, Spargo BH, Lindheimer MD: Hypertension in pregnancy: Clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 60: 267-276, 1981
45. Akbari A, Lepage N, Keely E, Clark HD, Jaffey J, MacKinnon M, Filler G: Cystatin-C and beta trace protein as markers of renal function in pregnancy. BJOG 112: 575-578, 2005
46. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R, Barron J, Lemmey A: GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 48: 712-719, 2006
47. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM: The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20: IX-XIV, 2001
48. Simanowitz MD, MacGregor WG: A critical evaluation of renal protein selectivity in pregnancy. J Obstet Gynaecol Br Commonw 81: 196-200, 1974
49. Winkler U, Lison AE, Seltzer B, Niedner W: Urinary protein patterns for early detection of preeclampsia. Contrib Nephrol 68: 227-229, 1988
50. Quaas L, Wilhelm C, Klosa W, Hillemanns HG, Thaiss F: Urinary protein patterns and EPH-gestosis. Clin Nephrol 27: 107-110, 1987
51. MacLean PR, Paterson WG, Smart GE, Petrie JJ, Robson JS, Thomson D: Proteinuria in toxaemia and abruptio placentae. J Obstet Gynaecol Br Commonw 79: 321-326, 1972
52. Moran P, Baylis PH, Lindheimer MD, Davison JM: Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 14: 648-652, 2003
53. Roberts JM: Endothelial dysfunction in preeclampsia. Semin Reprod Endocrinol 16: 5-15, 1998
54. Felfernig-Boehm D, Salat A, Vogl SE, Murabito M, Felfernig M, Schmidt D, Mittlboeck M, Husslein P, Mueller MR: Early detection of preeclampsia by determination of platelet aggregability. Thromb Res 98: 139-146, 2000
55. Ballegeer VC, Spitz B, De Baene LA, Van Assche AF, Hidajat M, Criel AM: Platelet activation and vascular damage in gestational hypertension. Am J Obstet Gynecol 166: 629-633, 1992
56. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet 359: 1877-1890, 2002
57. Manfredi M, Beltramello A, Bongiovanni LG, Polo A, Pistoia L, Rizzuto N: Eclamptic encephalopathy: Imaging and pathogenetic considerations. Acta Neurol Scand 96: 277-282, 1997
58. Schwartz RB, Feske SK, Polak JF, DeGirolami U, Iaia A, Beckner KM, Bravo SM, Klufas RA, Chai RY, Repke JT: Preeclampsia-eclampsia: Clinical and neuroradiographic correlates and insights into the pathogenesis of hypertensive encephalopathy. Radiology 217: 371-376, 2000
59. Demirtas O, Gelal F, Vidinli BD, Demirtas LO, Uluc E, Baloglu A: Cranial MR imaging with clinical correlation in preeclampsia and eclampsia. Diagn Interv Radiol 11: 189-194, 2005
60. Bakshi R, Shaikh ZA, Bates VE, Kinkel PR: Thrombotic thrombocytopenic purpura: Brain CT and MRI findings in 12 patients. Neurology 52: 1285-1288, 1999
61. Ito M, Itakura A, Olmo Y, Nomura M, Senga T, Nagasaka T, Mizutani S: Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia. J Clin Endocrinol Metab 87: 1871-1878, 2002
62. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fins-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658, 2003
63. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649, 2006
64. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683, 2004
65. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111: 707-716, 2003
66. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003
67. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278: 12605-12608, 2003
68. Bdolah Y, Palomaki GE, Yaron Y, Bdolah-Abram T, Goldman M, Levine RJ, Sachs BP, Haddow JE, Karumanchi SA: Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 194: 239-245, 2006
69. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA: Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 192: 734-741, 2005
70. Caniggia I, Taylor CV, Ritchie JW, Lye SJ, Letarte M: Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology 138: 4977-4988, 1997
71. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005, 2006